Patents Assigned to Aptissen SA
  • Injectable formulation of natural polysaccharide and polyol for treatment of osteoarthritis
    Patent number: 10028976
    Abstract: A sterile injectable aqueous formulation in the form of a gel made up of hyaluronic acid or a salt thereof and one or more polyols is provided. The gel formulation can be applied to the intra-articular area in the treatment of joint degeneration and osteoarthritis. The gel formulation has a rheology similar to that of synovial liquid and has an elevated resistance to degradation due to the synergistic action between the hyaluronic acid and the polyols.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: July 24, 2018
    Assignee: APTISSEN SA
    Inventors: Samuel Gavard Molliard, Olivier Benoit
  • Method for treating glaucoma
    Patent number: 9339514
    Abstract: A method of treating glaucoma or other eye disease in a patient is provided. The method includes injecting an eye of the patient with a cohesive monophasic gel containing cross-linked hyaluronic acid or its salt. The injection can be under the scleral flap and/or conjunctiva of the eye, thereby creating and maintaining a conjunctival bleb, and/or the injection can be in the supra-scleral and/or supra-choroidal (sub-scleral) space of the eye thereby reducing the intraocular pressure.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: May 17, 2016
    Assignee: APTISSEN SA
    Inventors: Gilles Bos, Philippe Sourdille
  • Use of a natural polysaccharide gel for the preparation of an injectable formulation for treatment of articular degeneration
    Patent number: 9138405
    Abstract: A sterile injectable aqueous formulation in the form of a gel is made up of hyaluronic acid (or one of the salts thereof) with or without other natural polysaccharide(s) and one or more polyols. The formulation is of intra-articular application in the treatment of joint degeneration, in some cases having a rheology similar to that of synovial liquid and always with an elevated resistance to degradation due to a synergistic action between the hyaluronic acid and the polyols.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: September 22, 2015
    Assignee: APTISSEN SA
    Inventors: Samuel Gavard Molliard, Olivier Benoit
  • METHOD FOR TREATING GLAUCOMA
    Publication number: 20140221972
    Abstract: A method of treating glaucoma or other eye disease in a patient is provided. The method includes injecting an eye of the patient with a cohesive monophasic gel containing cross-linked hyaluronic acid or its salt. The injection can be under the scleral flap and/or conjunctiva of the eye, thereby creating and maintaining a conjunctival bleb, and/or the injection can be in the supra-scleral and/or supra-choroidal (sub-scleral) space of the eye thereby reducing the intraocular pressure.
    Type: Application
    Filed: April 9, 2014
    Publication date: August 7, 2014
    Applicant: APTISSEN SA
    Inventors: Gilles BOS, Philippe SOURDILLE
  • Glaucoma surgery
    Patent number: 8715266
    Abstract: Eye diseases such as glaucoma can be treated using a composition containing cross-linked hyaluronic acid or a cross-linked salt of hyaluronic acid such as sodium hyalurate. The composition can be a monophasic gel. The composition can include a cross-linking agent such as 1,4-butanediol diglycidylether. The composition can contains about 2.25% (w/w) of the salt of hyaluronic acid. The composition can have a cross-linking rate of about 0.5 to 50%.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: May 6, 2014
    Assignee: Aptissen SA
    Inventor: Gilles Bos